DK3352584T3 - Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe - Google Patents
Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe Download PDFInfo
- Publication number
- DK3352584T3 DK3352584T3 DK16849423.5T DK16849423T DK3352584T3 DK 3352584 T3 DK3352584 T3 DK 3352584T3 DK 16849423 T DK16849423 T DK 16849423T DK 3352584 T3 DK3352584 T3 DK 3352584T3
- Authority
- DK
- Denmark
- Prior art keywords
- rna
- procedures
- synthesis
- compositions
- cover
- Prior art date
Links
- 0 C/C(/N)=N\c1c(C(N)=O)nc[n]1C(C1O)OC(COP(OC)(OC(C(COP(O)(OP(O)(OP(O)(OCC(C(C2O)O)OC2N(C=C)C(N=C(N)NC2=O)=C2[N+]C)=O)=O)=O)OC2N(C=CC(N=*)=N3)C3=O)C2OC)=O)C1O Chemical compound C/C(/N)=N\c1c(C(N)=O)nc[n]1C(C1O)OC(COP(OC)(OC(C(COP(O)(OP(O)(OP(O)(OCC(C(C2O)O)OC2N(C=C)C(N=C(N)NC2=O)=C2[N+]C)=O)=O)=O)OC2N(C=CC(N=*)=N3)C3=O)C2OC)=O)C1O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Paints Or Removers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221248P | 2015-09-21 | 2015-09-21 | |
| PCT/US2016/052670 WO2017053297A1 (en) | 2015-09-21 | 2016-09-20 | Compositions and methods for synthesizing 5'-capped rnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3352584T3 true DK3352584T3 (da) | 2021-07-12 |
Family
ID=58387109
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK23192203.0T DK4276189T3 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK22190426.1T DK4140491T5 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
| DK24186081.6T DK4424835T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe |
| DK22175377.5T DK4104687T5 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK23192203.0T DK4276189T3 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK22190426.1T DK4140491T5 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
| DK24186081.6T DK4424835T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe |
| DK22175377.5T DK4104687T5 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US10913768B2 (da) |
| EP (9) | EP4424835B1 (da) |
| JP (4) | JP6814997B2 (da) |
| KR (3) | KR20240095306A (da) |
| CN (8) | CN116751827B (da) |
| AU (5) | AU2016328645C1 (da) |
| CA (2) | CA3218662A1 (da) |
| CY (1) | CY1124306T1 (da) |
| DK (7) | DK4276189T3 (da) |
| ES (7) | ES2972098T3 (da) |
| FI (6) | FI4140491T3 (da) |
| HK (1) | HK1255236A1 (da) |
| HR (1) | HRP20211091T1 (da) |
| HU (5) | HUE065704T2 (da) |
| LT (7) | LT3906789T (da) |
| PL (7) | PL3954225T3 (da) |
| PT (7) | PT3352584T (da) |
| RS (1) | RS62129B1 (da) |
| SI (6) | SI4104687T1 (da) |
| SM (1) | SMT202100396T1 (da) |
| WO (1) | WO2017053297A1 (da) |
Families Citing this family (219)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| DK4276189T3 (da) | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| AU2018224387B2 (en) | 2017-02-22 | 2024-08-08 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| MX2019011215A (es) | 2017-03-24 | 2020-02-12 | Curevac Ag | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| WO2018208998A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| KR102773542B1 (ko) * | 2017-06-30 | 2025-02-25 | 코덱시스, 인코포레이티드 | T7 rna 폴리머라제 변이체 |
| JP2020530267A (ja) | 2017-06-30 | 2020-10-22 | コデクシス， インコーポレイテッド | Ｔ７ ｒｎａポリメラーゼバリアント |
| JP7722629B2 (ja) | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| IL311278B2 (en) | 2017-09-29 | 2026-05-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing |
| TWI904069B (zh) | 2017-09-29 | 2025-11-11 | 美商英特利亞醫療公司 | 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法 |
| CN112119084A (zh) * | 2018-03-15 | 2020-12-22 | 生物技术Rna制药有限公司 | 5′-帽三核苷酸或更高级寡核苷酸化合物及其在使rna稳定、表达蛋白质和治疗中的用途 |
| EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| CA3102135A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| AU2019410737A1 (en) | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
| CA3122645A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Methods for rna analysis |
| EP3920950A1 (en) | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| WO2020165158A1 (en) | 2019-02-11 | 2020-08-20 | Ethris Gmbh | Mrna purification by tangential flow filtration |
| MX2021010075A (es) * | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| KR20220004648A (ko) | 2019-03-28 | 2022-01-11 | 인텔리아 테라퓨틱스, 인크. | Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법 |
| MX2021011690A (es) | 2019-03-28 | 2022-01-06 | Intellia Therapeutics Inc | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este. |
| MX2021011757A (es) | 2019-03-28 | 2021-12-10 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para la expresión de polipéptidos. |
| US12637682B2 (en) * | 2019-04-16 | 2026-05-26 | The Regents Of The University Of California | Protein translational control |
| US20220362360A1 (en) * | 2019-04-26 | 2022-11-17 | Etherna Immunotherapies Nv | Mrna formulation |
| AU2020283751A1 (en) * | 2019-05-24 | 2021-12-23 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treatment of hemochromatosis |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| WO2021020979A1 (en) | 2019-07-31 | 2021-02-04 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
| WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
| JP2022546417A (ja) * | 2019-08-29 | 2022-11-04 | チューリッヒ大学 | 最小ｍＲＮＡおよびその使用 |
| CA3162019A1 (en) | 2019-12-20 | 2021-06-24 | Gemma NAVARRO | Lipid nanoparticles for delivery of nucleic acids |
| DE202021004130U1 (de) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL248416B1 (pl) * | 2020-02-12 | 2025-12-08 | Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN115175916B (zh) * | 2020-02-28 | 2025-02-14 | 国立研究开发法人科学技术振兴机构 | 加帽rna的制造方法 |
| CN113151312B (zh) * | 2020-03-02 | 2022-12-09 | 中国科学院微生物研究所 | 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用 |
| EP4114470A4 (en) | 2020-03-03 | 2024-04-17 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| AU2021250814A1 (en) | 2020-03-30 | 2022-10-13 | BioNTech SE | RNA compositions targeting Claudin-18.2 |
| WO2021216776A2 (en) | 2020-04-21 | 2021-10-28 | Gritstone Bio, Inc. | Capping compounds, compositions and methods of use thereof |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2021222801A2 (en) | 2020-05-01 | 2021-11-04 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
| CN115916978A (zh) | 2020-05-19 | 2023-04-04 | 哈德森医学研究所 | 寡核苷酸 |
| WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| WO2022006368A2 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| CN113122596B (zh) * | 2020-08-20 | 2023-01-24 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
| US20240246056A1 (en) | 2020-09-01 | 2024-07-25 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| CN116368226A (zh) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| CA3198727A1 (en) * | 2020-10-20 | 2022-04-28 | St Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
| WO2022112498A1 (en) | 2020-11-27 | 2022-06-02 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
| KR20230129432A (ko) | 2020-12-09 | 2023-09-08 | 비온테크 에스이 | Rna 제조 |
| EP4259792A1 (en) | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| AU2021412833A1 (en) | 2020-12-28 | 2023-07-06 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| CA3170747A1 (en) | 2021-01-27 | 2022-08-04 | Moritz THRAN | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CA3206549A1 (en) | 2021-01-29 | 2022-08-04 | Frederick G. Vogt | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| US20240122865A1 (en) | 2021-02-19 | 2024-04-18 | Pfizer Inc. | Methods of Protecting RNA |
| EP4313152A1 (en) | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
| KR20220140140A (ko) | 2021-04-09 | 2022-10-18 | 한미정밀화학주식회사 | 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| WO2022271780A1 (en) | 2021-06-22 | 2022-12-29 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
| US20240327444A1 (en) | 2021-07-05 | 2024-10-03 | Japan Science And Technology Agency | Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate |
| EP4116313A1 (en) | 2021-07-07 | 2023-01-11 | Westfälische Wilhelms-Universität Münster | Cap analog for the 5'-end of eukaryotic messenger rnas |
| KR20240042414A (ko) | 2021-07-29 | 2024-04-02 | 비온테크 에스이 | 흑색종의 치료용 조성물 및 방법 |
| EP4377331A2 (en) | 2021-07-30 | 2024-06-05 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
| WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| CN118978560A (zh) | 2021-08-27 | 2024-11-19 | 上海兆维科技发展有限公司 | 一种加帽类似物及其应用 |
| US20240352496A1 (en) * | 2021-08-31 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Ivt rna manufacturing process |
| CA3230030A1 (en) * | 2021-08-31 | 2023-03-09 | Bo Sung Choi | Mrna cap analogue and use thereof |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| IL309502A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine |
| CN113957108B (zh) * | 2021-09-09 | 2025-01-10 | 上海兆维科技发展有限公司 | 一种加帽rna的合成方法以及加帽rna转录反应液 |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4402149A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| JP2024543721A (ja) | 2021-10-22 | 2024-11-22 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖複合体及び用途 |
| WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| US20250002522A1 (en) | 2021-10-22 | 2025-01-02 | BioNTech SE | Oligosaccharide compounds and complexes |
| JP2024540979A (ja) | 2021-10-22 | 2024-11-06 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖複合体及び用途 |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4426822A2 (en) | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20230083197A (ko) | 2021-12-01 | 2023-06-09 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| WO2023115495A1 (zh) * | 2021-12-23 | 2023-06-29 | 北京毅新博创生物科技有限公司 | 质谱法检测mRNA加帽效率的方法 |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| EP4469065A1 (en) | 2022-01-28 | 2024-12-04 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| KR20230123318A (ko) | 2022-02-16 | 2023-08-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| GB2615784A (en) | 2022-02-18 | 2023-08-23 | Phion Therapeutics Ltd | mRNA vaccine |
| CN115260264B (zh) | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| WO2023167880A2 (en) * | 2022-03-01 | 2023-09-07 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| US20230293646A1 (en) | 2022-03-21 | 2023-09-21 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
| US12522630B2 (en) | 2022-03-31 | 2026-01-13 | Hanmi Fine Chemical Co., Ltd. | MRNA cap analog and uses thereof |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| GB2618818A (en) | 2022-05-18 | 2023-11-22 | Phion Therapeutics Ltd | Vaccine |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| US20250375534A1 (en) | 2022-05-30 | 2025-12-11 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2023235422A2 (en) * | 2022-05-31 | 2023-12-07 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2023235362A1 (en) * | 2022-05-31 | 2023-12-07 | Nutcracker Therapeutics, Inc. | Rna cap analogs and methods of use |
| CN119384498A (zh) | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| CN114853836B (zh) * | 2022-06-24 | 2024-05-14 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110B (zh) * | 2022-06-22 | 2024-07-12 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| CN114941018B (zh) * | 2022-06-28 | 2023-09-22 | 翌圣生物科技(上海)股份有限公司 | cap1帽类似物的合成方法 |
| KR20240010238A (ko) | 2022-07-15 | 2024-01-23 | 한미정밀화학주식회사 | 캡 유사체 및 이의 용도 |
| CN117430652A (zh) * | 2022-07-22 | 2024-01-23 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的环状取代化合物及其应用 |
| US11898186B1 (en) | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| CN115925773A (zh) * | 2022-08-23 | 2023-04-07 | 合肥华纳生物医药科技有限公司 | 一种新型信使核糖核酸帽类似物 |
| CA3265304A1 (en) * | 2022-08-26 | 2024-02-29 | Trilink Biotechnologies, Llc | EFFICIENT PROCESS FOR PRODUCING HIGHLY PURIFIED 5' CAP OLIGONUCLEOTIDES |
| WO2024051696A1 (zh) * | 2022-09-05 | 2024-03-14 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| JP2025531877A (ja) | 2022-09-09 | 2025-09-25 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| JP2025532191A (ja) | 2022-09-26 | 2025-09-29 | ビオンテック・ソシエタス・エウロパエア | 核酸複合体及びその使用 |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| IL319652A (en) | 2022-10-04 | 2025-05-01 | BioNTech SE | RNA structures and their uses |
| CN120129702A (zh) | 2022-10-06 | 2025-06-10 | 生物技术公司 | 靶向密蛋白-18.2的rna组合物 |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4605010A1 (en) | 2022-10-21 | 2025-08-27 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| CN116143855B (zh) * | 2022-11-08 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用 |
| CN120418427A (zh) | 2022-12-23 | 2025-08-01 | 因特利亚治疗公司 | 用于基因组编辑的系统和方法 |
| EP4397669A1 (en) | 2023-01-06 | 2024-07-10 | Westfälische Wilhelms-Universität Münster | Photocaged cap analogs for the 5'-end of rnas |
| JP2026501855A (ja) | 2023-01-20 | 2026-01-16 | アストラゼネカ・アクチエボラーグ | ワクチン |
| AU2024209872A1 (en) | 2023-01-20 | 2025-09-04 | Astrazeneca Ab | Nucleic acid molecules |
| US20260226091A1 (en) | 2023-01-31 | 2026-08-06 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| KR20250157528A (ko) | 2023-03-03 | 2025-11-04 | 나티아스 인크. | 폴리인산화 뉴클레오시드, 폴리인산화 뉴클레오시드의 합성에 사용되는 인산부 활성화 뉴클레오티드 및 그 합성 방법, 및 인산부 활성화 뉴클레오티드를 사용한 폴리인산화 뉴클레오시드의 합성 방법 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| CN116239642A (zh) * | 2023-03-13 | 2023-06-09 | 上海兆维科技发展有限公司 | 加帽聚核苷酸、加帽mRNA及组合物、药物蛋白及制备方法和应用、药物制剂 |
| CN116356002A (zh) * | 2023-03-28 | 2023-06-30 | 四川康德赛医疗科技有限公司 | 一种rna加帽效率的定量方法、试剂盒及其应用 |
| WO2024206555A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| TW202444914A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 抑制子融合蛋白系統 |
| CN118726510A (zh) * | 2023-03-31 | 2024-10-01 | 苏州近岸蛋白质科技股份有限公司 | 一管法酶促合成加帽mRNA的方法 |
| CN118772219B (zh) * | 2023-04-04 | 2025-12-02 | 深圳瑞吉生物科技有限公司 | 一种用于核酸的5’端加帽的含卤化合物及其应用 |
| JP2026518411A (ja) | 2023-04-27 | 2026-06-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | インフルエンザウイルスワクチン |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| EP4713483A1 (en) | 2023-05-16 | 2026-03-25 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| KR20260018077A (ko) | 2023-05-26 | 2026-02-06 | 큐어백 에스이 | 암 항원 |
| EP4731655A1 (en) | 2023-06-23 | 2026-04-29 | CureVac SE | Nucleic acid encoded antibodies |
| CN121752579A (zh) | 2023-06-29 | 2026-03-27 | 胡桃夹子治疗公司 | 乙基修饰的rna帽和使用方法 |
| WO2025022290A1 (en) | 2023-07-21 | 2025-01-30 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| TW202519509A (zh) | 2023-08-01 | 2025-05-16 | 德商拜恩技術股份公司 | 可離子化硫脂質及其用途 |
| EP4761761A1 (en) | 2023-08-16 | 2026-06-24 | CureVac SE | Rna conjugates |
| CN117362360A (zh) * | 2023-08-21 | 2024-01-09 | 星锐医药(苏州)有限公司 | 一种帽类似物的制备方法 |
| EP4774281A2 (en) * | 2023-09-06 | 2026-07-15 | TriLink BioTechnologies, LLC | Cap analogs and methods of use thereof |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025071359A1 (ko) | 2023-09-27 | 2025-04-03 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
| AU2024374554A1 (en) | 2023-11-10 | 2026-05-21 | Intellia Therapeutics, Inc. | Compositions, methods, and systems for genomic editing |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025134062A2 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025147660A2 (en) | 2024-01-04 | 2025-07-10 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
| CN117534719B (zh) | 2024-01-09 | 2024-05-14 | 北京悦康科创医药科技股份有限公司 | 一种c6'取代锁核酸修饰加帽类似物及其应用 |
| WO2025168058A1 (zh) | 2024-02-08 | 2025-08-14 | 江苏申基生物科技有限公司 | 新的mRNA加帽化合物及其应用 |
| WO2025181704A2 (en) | 2024-02-27 | 2025-09-04 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025208142A2 (en) | 2024-03-29 | 2025-10-02 | New England Biolabs, Inc. | Compositions, kits, and methods for in vitro transcription |
| EP4650358A3 (en) | 2024-04-26 | 2026-01-14 | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Ribose-modified cap analog and use thereof |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
| TW202617177A (zh) | 2024-06-18 | 2026-05-01 | 德商拜恩技術股份公司 | 用於治療黑色素瘤之組合物及方法 |
| WO2025262460A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Lipid compositions for nucleic acid delivery |
| WO2026010855A1 (en) | 2024-07-02 | 2026-01-08 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
| WO2026033380A1 (en) | 2024-08-05 | 2026-02-12 | BioNTech SE | Process for preparing oligosaccharide complexes |
| WO2026078020A2 (en) | 2024-10-07 | 2026-04-16 | Explorna Therapeutics Sp. Z O. O. | Efficient in vitro transcription of artificial mrna with highly modified 5' ends |
| EP4722375A1 (en) | 2024-10-07 | 2026-04-08 | ExploRNA Therapeutics Sp. z o. o. | Efficient in vitro transcription of artificial mrna with highly modified 5' ends |
| WO2026097018A1 (en) | 2024-11-04 | 2026-05-07 | Intellia Therapeutics, Inc. | Polypeptides, polynucleotides, compositions, and methods for genome editing involving chromatin remodelers |
| WO2026104647A1 (en) | 2024-11-15 | 2026-05-21 | Astrazeneca Ab | Vaccine |
| CN120608113B (zh) * | 2024-11-29 | 2026-04-10 | 上海蓝鹊生物医药有限公司 | 一种合成Cap2结构5'-加帽RNA的组合和方法 |
| CN119306779A (zh) * | 2024-12-13 | 2025-01-14 | 上海科泽永欣生物科技有限公司 | 一种含r构型的起始加帽寡核苷酸引物及其合成方法 |
| US20260185136A1 (en) * | 2024-12-27 | 2026-07-02 | Eisai R&D Management Co., Ltd. | 5'-cap modifications of rna |
| WO2026164049A1 (ja) * | 2025-01-30 | 2026-08-06 | ヤマサ醤油株式会社 | 核酸の化学構造を分析するための組成物、核酸の化学構造分析用試料の製造方法、および核酸の化学構造分析方法 |
| WO2026163162A1 (en) | 2025-01-31 | 2026-08-06 | Intellia Therapeutics, Inc. | Enhanced cas9 variants and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997A (en) | 1841-03-03 | Improvement in the mode of rendering fabrics water-proof | ||
| EP0081099A3 (en) * | 1981-12-04 | 1983-08-10 | Sloan-Kettering Institute For Cancer Research | Capped oligonucleotide anti-viral agents |
| DE3148702C2 (de) * | 1981-12-09 | 1985-05-15 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte |
| US5837852A (en) | 1993-10-14 | 1998-11-17 | Bristol-Myers Squibb Company | Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease |
| EP1163251A1 (en) | 1999-03-24 | 2001-12-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | N-acylphosphoramidites and their use in oligonucleotide synthesis |
| US7074596B2 (en) * | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7629325B2 (en) * | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| WO2006063252A2 (en) | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| CN101437943A (zh) * | 2006-05-03 | 2009-05-20 | 波罗的科技发展有限公司 | 牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂 |
| JP5558811B2 (ja) | 2006-06-01 | 2014-07-23 | トリリンク バイオテクノロジーズ | 核酸増幅のための化学的に修飾されたオリゴヌクレオチドプライマー |
| EP2049665A2 (en) * | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| US20080248469A1 (en) | 2006-08-16 | 2008-10-09 | Applera Corporation | Methods for Identifying Nucleotides of Interest in Target Polynucleotides |
| US8153773B2 (en) | 2007-06-19 | 2012-04-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap |
| WO2009058911A2 (en) * | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US9067964B2 (en) * | 2008-12-18 | 2015-06-30 | Oligomer Sciences Ab | Complex and method for enhancing nuclear delivery |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| WO2011157617A1 (en) | 2010-06-17 | 2011-12-22 | Febit Holding Gmbh | Complex set of mirna libraries |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| JP5923303B2 (ja) * | 2011-12-28 | 2016-05-24 | 公益財団法人微生物化学研究会 | 新規キャッピング酵素、並びに、キャップ化ｒｎａの製造方法及びその用途 |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| EA201591229A1 (ru) * | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| MX2015011945A (es) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Evaluacion cuantitativa para la eficacia de los casquetes de arn mensajero. |
| JP6148592B2 (ja) | 2013-10-15 | 2017-06-14 | ヤマハ発動機株式会社 | 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両 |
| US10676499B2 (en) | 2014-12-16 | 2020-06-09 | Novartis Ag | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA |
| DK4276189T3 (da) * | 2015-09-21 | 2026-05-26 | Trilink Biotechnologies Llc | Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| CN112119084A (zh) | 2018-03-15 | 2020-12-22 | 生物技术Rna制药有限公司 | 5′-帽三核苷酸或更高级寡核苷酸化合物及其在使rna稳定、表达蛋白质和治疗中的用途 |
| US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
| PL248416B1 (pl) † | 2020-02-12 | 2025-12-08 | Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| WO2022006368A2 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| CA3198727A1 (en) | 2020-10-20 | 2022-04-28 | St Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
-
2016
- 2016-09-20 DK DK23192203.0T patent/DK4276189T3/da active
- 2016-09-20 SI SI201631802T patent/SI4104687T1/sl unknown
- 2016-09-20 CN CN202310734863.0A patent/CN116751827B/zh not_active Ceased
- 2016-09-20 ES ES22175377T patent/ES2972098T3/es active Active
- 2016-09-20 HK HK18114366.7A patent/HK1255236A1/zh unknown
- 2016-09-20 SI SI201631757T patent/SI4140491T1/sl unknown
- 2016-09-20 HU HUE22175377A patent/HUE065704T2/hu unknown
- 2016-09-20 HU HUE16849423A patent/HUE055458T2/hu unknown
- 2016-09-20 WO PCT/US2016/052670 patent/WO2017053297A1/en not_active Ceased
- 2016-09-20 SI SI201631248T patent/SI3352584T1/sl unknown
- 2016-09-20 EP EP24186081.6A patent/EP4424835B1/en active Active
- 2016-09-20 EP EP16849423.5A patent/EP3352584B1/en not_active Revoked
- 2016-09-20 CN CN202211046591.7A patent/CN116590285A/zh active Pending
- 2016-09-20 DK DK21173278.9T patent/DK3906789T5/da active
- 2016-09-20 LT LTEP21173278.9T patent/LT3906789T/lt unknown
- 2016-09-20 HU HUE21173278A patent/HUE065203T2/hu unknown
- 2016-09-20 FI FIEP22190426.1T patent/FI4140491T3/fi active
- 2016-09-20 CN CN202511246578.XA patent/CN121064267B/zh active Active
- 2016-09-20 PL PL21173142.7T patent/PL3954225T3/pl unknown
- 2016-09-20 LT LTEP23192203.0T patent/LT4276189T/lt unknown
- 2016-09-20 PL PL16849423T patent/PL3352584T3/pl unknown
- 2016-09-20 PL PL24186081.6T patent/PL4424835T3/pl unknown
- 2016-09-20 PL PL22175377.5T patent/PL4104687T3/pl unknown
- 2016-09-20 EP EP21173278.9A patent/EP3906789B2/en active Active
- 2016-09-20 RS RS20210857A patent/RS62129B1/sr unknown
- 2016-09-20 EP EP21173131.0A patent/EP3954224A1/en active Pending
- 2016-09-20 CA CA3218662A patent/CA3218662A1/en active Pending
- 2016-09-20 EP EP22190426.1A patent/EP4140491B1/en not_active Revoked
- 2016-09-20 PT PT168494235T patent/PT3352584T/pt unknown
- 2016-09-20 SI SI201631954T patent/SI4276189T1/sl unknown
- 2016-09-20 ES ES16849423T patent/ES2879686T3/es active Active
- 2016-09-20 FI FIEP21173278.9T patent/FI3906789T3/fi active
- 2016-09-20 PT PT221753775T patent/PT4104687T/pt unknown
- 2016-09-20 PT PT241860816T patent/PT4424835T/pt unknown
- 2016-09-20 CN CN202511246658.5A patent/CN121085982A/zh active Pending
- 2016-09-20 HU HUE21173142A patent/HUE065331T2/hu unknown
- 2016-09-20 EP EP23192203.0A patent/EP4276189B1/en active Active
- 2016-09-20 HR HRP20211091TT patent/HRP20211091T1/hr unknown
- 2016-09-20 PT PT211731427T patent/PT3954225T/pt unknown
- 2016-09-20 FI FIEP22175377.5T patent/FI4104687T3/fi active
- 2016-09-20 SM SM20210396T patent/SMT202100396T1/it unknown
- 2016-09-20 AU AU2016328645A patent/AU2016328645C1/en active Active
- 2016-09-20 FI FIEP23192203.0T patent/FI4276189T3/fi active
- 2016-09-20 DK DK21173142.7T patent/DK3954225T5/da active
- 2016-09-20 LT LTEP22175377.5T patent/LT4104687T/lt unknown
- 2016-09-20 SI SI201631773T patent/SI3954225T1/sl unknown
- 2016-09-20 US US15/761,957 patent/US10913768B2/en active Active
- 2016-09-20 LT LTEP22190426.1T patent/LT4140491T/lt unknown
- 2016-09-20 CN CN202110537080.4A patent/CN113584020A/zh active Pending
- 2016-09-20 DK DK22190426.1T patent/DK4140491T5/da active
- 2016-09-20 PT PT231922030T patent/PT4276189T/pt unknown
- 2016-09-20 LT LTEP24186081.6T patent/LT4424835T/lt unknown
- 2016-09-20 ES ES21173278T patent/ES2968335T3/es active Active
- 2016-09-20 PL PL21173278.9T patent/PL3906789T3/pl unknown
- 2016-09-20 FI FIEP21173142.7T patent/FI3954225T3/fi active
- 2016-09-20 EP EP21173142.7A patent/EP3954225B1/en active Active
- 2016-09-20 LT LTEP16849423.5T patent/LT3352584T/lt unknown
- 2016-09-20 EP EP25219223.2A patent/EP4717779A3/en active Pending
- 2016-09-20 KR KR1020247017688A patent/KR20240095306A/ko active Pending
- 2016-09-20 ES ES23192203T patent/ES3068657T3/es active Active
- 2016-09-20 ES ES22190426T patent/ES2964690T3/es active Active
- 2016-09-20 ES ES24186081T patent/ES3065460T3/es active Active
- 2016-09-20 HU HUE22190426A patent/HUE064227T2/hu unknown
- 2016-09-20 CN CN201680067458.6A patent/CN108366604A/zh active Pending
- 2016-09-20 SI SI201631772T patent/SI3906789T1/sl unknown
- 2016-09-20 KR KR1020237004950A patent/KR102670937B1/ko active Active
- 2016-09-20 FI FIEP24186081.6T patent/FI4424835T3/fi active
- 2016-09-20 PL PL22190426.1T patent/PL4140491T3/pl unknown
- 2016-09-20 JP JP2018515136A patent/JP6814997B2/ja active Active
- 2016-09-20 DK DK24186081.6T patent/DK4424835T3/da active
- 2016-09-20 LT LTEP21173142.7T patent/LT3954225T/lt unknown
- 2016-09-20 PT PT211732789T patent/PT3906789T/pt unknown
- 2016-09-20 ES ES21173142T patent/ES2968391T3/es active Active
- 2016-09-20 CN CN202311200887.4A patent/CN117025590A/zh active Pending
- 2016-09-20 EP EP22175377.5A patent/EP4104687B2/en active Active
- 2016-09-20 CN CN202511246712.6A patent/CN120842296A/zh active Pending
- 2016-09-20 CA CA2999274A patent/CA2999274C/en active Active
- 2016-09-20 PL PL23192203.0T patent/PL4276189T3/pl unknown
- 2016-09-20 DK DK22175377.5T patent/DK4104687T5/da active
- 2016-09-20 DK DK16849423.5T patent/DK3352584T3/da active
- 2016-09-20 KR KR1020187010893A patent/KR102500198B1/ko active Active
- 2016-09-20 PT PT221904261T patent/PT4140491T/pt unknown
-
2018
- 2018-12-26 US US16/232,435 patent/US10519189B2/en active Active
-
2019
- 2019-04-01 US US16/371,317 patent/US10494399B2/en active Active
-
2020
- 2020-11-06 US US17/091,422 patent/US11878991B2/en active Active
- 2020-12-10 JP JP2020204713A patent/JP7082174B2/ja active Active
-
2021
- 2021-07-07 CY CY20211100612T patent/CY1124306T1/el unknown
- 2021-07-19 AU AU2021206780A patent/AU2021206780C1/en active Active
- 2021-08-02 US US17/392,170 patent/US11414453B2/en active Active
-
2022
- 2022-04-22 JP JP2022070512A patent/JP7594563B2/ja active Active
- 2022-05-26 US US17/804,192 patent/US11578095B2/en active Active
-
2023
- 2023-03-29 AU AU2023201915A patent/AU2023201915B2/en active Active
- 2023-09-13 AU AU2023229522A patent/AU2023229522B2/en active Active
- 2023-09-14 US US18/467,224 patent/US12258369B2/en active Active
-
2024
- 2024-01-09 US US18/408,431 patent/US12103944B2/en active Active
- 2024-06-26 JP JP2024102548A patent/JP2024150459A/ja active Pending
-
2025
- 2025-01-17 US US19/028,051 patent/US20250171489A1/en active Pending
- 2025-05-13 AU AU2025203425A patent/AU2025203425A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
| DK3303317T3 (da) | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner | |
| DK4104687T3 (da) | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe | |
| EP3445407A4 (en) | COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY | |
| DK3510157T5 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
| DK3600270T3 (da) | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser | |
| DK3595653T3 (da) | Sammensætninger af plinabulin og anvendelse heraf | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3827845T3 (da) | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf | |
| DK3286181T3 (da) | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3518933T3 (da) | Fremgangsmåder til behandling af uterusfibromer og endometriose | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3606929T3 (da) | Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme | |
| HUE065438T2 (hu) | Vegyületek, készítmények és alkalmazási eljárások | |
| DK3607050T3 (da) | Ex vivo-dyrkningssystem og metoder til brugen af samme | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne |